What is N2B's primary focus?

N2B is focused on the treatment of depression associated with Parkinson's disease (PD) through the development of an intranasal delivery formulation of the approved drug Rasagiline.

When was N2B founded?

N2B was founded in January 2015.

What is the current status of N2B?

N2B is currently inactive, having ceased operations in August 2017.

Which organization provided funding to N2B?

N2B received funding from the Office of the Chief Scientist and Youdim Pharmaceuticals in 2015.

What is N2B's employee count?

N2B has an employee count in the 1-10 range.

What is N2B's regulatory strategy for its drug formulation?

N2B is pursuing a quick regulatory pathway for NDA submission through the U.S. FDA 505(b)(2) approach for its intranasal Rasagiline formulation.

What are the potential benefits of N2B's intranasal Rasagiline delivery?

N2B's preclinical results suggest that intranasal delivery of Rasagiline could offer an alternative to oral administration for PD treatment and a novel therapeutic approach for depression in PD patients.

Where is N2B headquartered?

N2B is headquartered in Yokne'am Illit, North District, Israel.

N2B

Treatment of Parkinsons-related Depression

Health Tech & Life Sciences

Non Active, Aug 2017 ceased to operate

Seed Yokne'am Illit, Israel Founded 2015

Last updated 2026-06-18

Raised funding round, Jan 2015
Raised grant

Total raised

—

Last: 2015-01

Stage

Seed

Founded

2015

Headcount

Yokne'am Illit, Israel

Sector

Health Tech & Life Sciences

About

N2B Ltd is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinsons disease (PD). The company is on a quick regulatory pathway for NDA submission through the U.S. FDA 5O5(b)(2) approach. N2Bs preclinical results indicate that intranasal delivery of Rasagiline could provide both a useful alternative to oral administration in the treatment of PD and a novel therapeutic approach for the treatment of depression in PD patients. N2B was founded as an incubator company of Youdim Pharmaceuticals.

Funding history · 2 rounds · — total

2015-01

Undisclosed

Youdim Pharmaceuticals

Date unknown

Grant Undisclosed

Office of the Chief Scientist

Q&A

What is N2B's primary focus?: N2B is focused on the treatment of depression associated with Parkinson's disease (PD) through the development of an intranasal delivery formulation of the approved drug Rasagiline.
When was N2B founded?: N2B was founded in January 2015.
What is the current status of N2B?: N2B is currently inactive, having ceased operations in August 2017.
Which organization provided funding to N2B?: N2B received funding from the Office of the Chief Scientist and Youdim Pharmaceuticals in 2015.
What is N2B's employee count?: N2B has an employee count in the 1-10 range.
What is N2B's regulatory strategy for its drug formulation?: N2B is pursuing a quick regulatory pathway for NDA submission through the U.S. FDA 505(b)(2) approach for its intranasal Rasagiline formulation.
What are the potential benefits of N2B's intranasal Rasagiline delivery?: N2B's preclinical results suggest that intranasal delivery of Rasagiline could offer an alternative to oral administration for PD treatment and a novel therapeutic approach for depression in PD patients.
Where is N2B headquartered?: N2B is headquartered in Yokne'am Illit, North District, Israel.

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics

Technologies

Biologicals

Target customers

Healthcare & Life SciencesHealthcarePatients

Business model

B2B

Highlights

1 PatentsVerified

Identifiers & details

Founded	2015-1
Employees (exact)	6
Status reason	Non Active, Aug 2017 ceased to operate

About

Funding history · 2 rounds · — total

Q&A

Sectors & technology

Highlights

Tags

Identifiers & details

Generate Slim Page